Covista (CVSA) Earnings Analysis
Covista (CVSA) has no confirmed upcoming earnings date. Last quarter (2026-05-07) it beat with EPS 1.98 USD vs 1.73 USD est (+14.5%). It has beaten estimates in 7/7 recent quarters (100%). Trailing P/E 15.97.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does CVSA next report earnings?
No confirmed upcoming earnings date is currently scheduled for CVSA. This page updates as the calendar is published.
CVSA earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | 1.98 USD | 1.73 USD | +14.5% | Beat |
| 2026-01-28 | 2.43 USD | 2.19 USD | +11% | Beat |
| 2025-10-30 | 1.75 USD | 1.57 USD | +11.5% | Beat |
| 2025-08-07 | 1.66 USD | 1.53 USD | +8.5% | Beat |
| 2025-05-08 | 1.92 USD | 1.65 USD | +16.4% | Beat |
| 2024-12-31 | 1.98 USD | 1.37 USD | +44.5% | Beat |
| 2024-09-30 | 1.18 USD | 1.13 USD | +4.4% | Beat |
Beat rate: 7/7 (100%) over reported quarters with consensus data.
CVSA valuation and analyst view
| Trailing P/E | 15.97 |
|---|---|
| Trailing EPS | 6.827 USD |
| Price / book | 2.82 |
| Dividend yield | 0.00% |
| Market cap | 3.75B |
| Analyst consensus | Buy (2 buy / 0 hold / 0 sell) |
| Avg price target | 140 USD |
Related research pages
Frequently asked questions
When is Covista (CVSA)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for CVSA. This page updates as the calendar is published.
Did CVSA beat earnings last quarter?
In its 2026-05-07 report, CVSA posted EPS of 1.98 USD versus a 1.73 USD estimate — a beat of 14.5%.
What is CVSA's earnings track record?
Over the last 7 reported quarters with consensus data, CVSA beat estimates 7 times (100%).
What is CVSA's current P/E ratio and EPS?
CVSA trades at a trailing P/E of 15.97 on trailing EPS of 6.82720298690313 USD.
What do analysts rate CVSA?
Analyst consensus is "Buy" across 2 ratings (0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 140 USD.